-

09:28:11 PM

URGN Stock News

URGN - UroGen Pharma Ltd

09/08/23 8:00 AM

Nasdaq : URGN

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units to 11 new employees, as well as options to one of the new employees, in connection with their employment with UroGen. These new team members will...

RHEA-AI

very positive

08/31/23 8:00 AM

Nasdaq : URGN

conferences

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in September:. Wainwright 25th Annual Global Investment Conference— September 11-13, 2023. Presentation: Tuesday, September 12 th at...

RHEA-AI

neutral

08/10/23 8:00 AM

Nasdaq : URGN

UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments

If approved, we believe UGN-102’ s promising efficacy and safety profile across multiple trials support a potential shift from frequent surgeries to a minimally invasive, non-surgical option for the more than 82,000 underserved LG-IR-NMIBC patients diagnosed annually in the U.S. alone, positioning it as a potential key growth driver for UroGen.”.

RHEA-AI

neutral

08/08/23 8:00 AM

Nasdaq : URGN

The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that The Journal of Urology published data from the Phase 3 ATLAS trial for investigational agent UGN-102 for intravesical solution in patients with low-grade, intermediate-risk non-muscle...

RHEA-AI

positive

08/02/23 5:00 PM

Nasdaq : URGN

conferencesearnings

UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2023 financial results on Thursday, August 10, 2023, prior to the open of the market. The announcement will be followed by a live audio webcast and conference...

RHEA-AI

neutral

07/31/23 8:00 AM

Nasdaq : URGN

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units and options to a new employee, Michael Louie, SVP Medical Affairs& Clinical Development, in connection with his commencing employment with...

RHEA-AI

very positive

07/27/23 9:55 AM

Nasdaq : URGN

UroGen Announces $120 Million Private Placement of Ordinary Shares

UroGen expects to receive gross proceeds of approximately $120 million, before deducting placement agent commissions and other offering expenses. Pursuant to the terms of the securities purchase agreement, UroGen will issue 12,579,156 ordinary shares, or pre-funded warrants in lieu thereof, at a purchase price of $9.54 per share, which reflects a premium...

RHEA-AI

neutral

07/27/23 9:50 AM

Nasdaq : URGN

clinical trial

UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced positive topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.

RHEA-AI

neutral

07/25/23 4:10 PM

Nasdaq : URGN

management

UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

Robinson has excelled in building and leading organizations from inception to commercial success. Robinson was President and COO at Paragon Biosciences. He also held prominent roles at Astellas U.S. and Schering-Plough Pharmaceuticals, focusing on commercial operations and sales.

RHEA-AI

positive

07/10/23 8:00 AM

Nasdaq : URGN

Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first post-commercial utilization review of JELMYTO for pyelocalyceal solution. This study assessed the efficacy of JELMYTO in managing patients...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

URGN Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttp://www.urogen.com
Security nameUroGen Pharma Ltd
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountryIsrael

About UroGen Pharma Ltd

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.